Causes of death in the ATLAS study: effects of high-dose ACE inhibitors.
作者信息
Cleland J G
机构信息
University of Glasgow, UK.
出版信息
Int J Clin Pract Suppl. 1999 Apr;100:19-20.
PMID:10658295
Abstract
摘要
相似文献
1
Causes of death in the ATLAS study: effects of high-dose ACE inhibitors.
Int J Clin Pract Suppl. 1999 Apr;100:19-20.
2
What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
J Card Fail. 2000 Jun;6(2):165-8.
3
Results of the ATLAS study.
Int J Clin Pract Suppl. 1999 Apr;100:17-8.
4
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
Eur Heart J. 2000 Dec;21(23):1967-78. doi: 10.1053/euhj.2000.2311.
5
The ATLAS study: low-dose versus high-dose lisinopril in heart failure.
Int J Clin Pract Suppl. 1999 Apr;100:15-6.
6
Implications of the ATLAS study for clinical practice.
Int J Clin Pract Suppl. 1999 Apr;100:21-3.
7
Assessment of Treatment with Lisinopril and Survival ATLAS study.
Int J Clin Pract Suppl. 1999 Apr;100:24.
8
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
Eur Heart J. 2001 Sep;22(17):1601-12. doi: 10.1053/euhj.2000.2570.
9
Is more better? About dose levels of ACE inhibitors in chronic heart failure.
Eur Heart J. 2000 Dec;21(23):1902-3. doi: 10.1053/euhj.2000.2436.
10
ATLAS: high dose lisinopril is superior to low dose in heart failure.
Int J Clin Pract. 1998 Apr-May;52(3):139.
Zotero 插件